A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer

Pharmacogenomics Journal

Volumn 13, Issue 5, 2013, Pages 417-422

  Han, J Y ^a   Shin, E S ^b   Lee, Y S ^a   Ghang, H Y ^c   Kim, S Y ^a   Hwang, J A ^a   Kim, J Y ^a   Lee, J S ^a  

^a National Cancer Center   (South Korea)

^b DNA Link Inc   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

C8orf34; FLJ41856; irinotecan; PDZRN3; PLCB1; SEMA3C

Indexed keywords

CAPECITABINE; CISPLATIN; IRINOTECAN; PHOSPHOLIPASE C BETA1;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 2 PSEUDOGENE; CHROMOSOME 8 OPEN READING FRAME 34 GENE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PDZ DOMAIN CONTAINING RING FINGER 3 GENE; PHOSPHOLIPASE C BETA1 GENE; PRIORITY JOURNAL; PROMOTER REGION; SEMAPHORIN 3C GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 84884624822     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.24     Document Type: Article

References (26)

1. Van Cutsem E, Douillard JY, Kohne CH. Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 2001; 345: 1351-1352.
2. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDPglucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
3. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T et al. UGT1A1 28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
4. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
5. de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81: 42-49.
6. Iyer L, Ramírez J, Shepard DR, Bingham CM, Hossfeld DK, Ratain MJ et al. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 2002; 49: 336-341.
7. Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 2000; 922: 188-194.
8. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005; 33: 434-439.
9. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237-2244.
10. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138-147.
11. Han JY, Lim HS, Lee SY, Kim HT, Lee JS. Influence of the organic anion transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan- pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 2008; 59: 69-75.
12. Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 2009; 63: 115-120.
13. Savas S, Liu G. Genetic variations as cancer prognostic markers: review and update. Hum Mutat 2009; 30: 1369-1377.
14. Han JY, Lee DH, Song JE, Lee SY, Kim HY, Kim HT et al. Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2006; 106: 873-880.
15. Han JY, Lim HS, Lee DH, Ju SY, Lee SY, Kim HY et al. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. Cancer 2008; 113: 388-395.
16. Söderlund-Strand A, Dillner J, Carlson J. High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem 2008; 54: 86-92.
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
18. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies via imputation of genotypes. Nat Genet 2007; 39: 906-913.
19. Bowen JM, Gibson RJ, Tsykin A, Stringer AM, Logan RM, Keefe DM. Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer 2007; 121: 1847-1856.
20. Haritunians T, Taylor KD, Targan SR, Dubinsky M, Ippoliti A, Kwon S et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 2010; 16: 1830-1840.
21. Blumenstein I, Keserü B, Wolter F, Stein J. The chemopreventive agent resveratrol stimulates cyclic AMP-dependent chloride secretion in vitro. Clin Cancer Res 2005; 11: 5651-5656.
22. Ko JA, Kimura Y, Matsuura K, Yamamoto H, Gondo T, Inui M. PDZRN3 (LNX3, SEMCAP3) is required for the differentiation of C2C12 myoblasts into myotubes. J Cell Sci 2006; 119: 5106-5113.
23. Honda T, Yamamoto H, Ishii A, Inui M. PDZRN3 negatively regulates BMP-2-induced osteoblast differentiation through inhibition of Wnt signaling. Mol Biol Cell 2010; 21: 3269-3277.
24. Miller G, Socci ND, Dhall D, D'Angelica M, DeMatteo RP, Allen PJ et al. Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res 2009; 28: 62.
25. Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 2009; 18: 2700-2710.
26. Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, Batzler AJ et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2011; 17: 5801-5811.